CCK and GLP1 are implicated in neuroprotection and neurite outgrowth within the central nervous system (CNS) [35, 36], with GLP1R agonists offering therapeutic avenues for Alzheimer's and Parkinson's disease [37, 38, 39]. This evidence concerns the gene GLP1R and Parkinson disease.